Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

A 21-year-old male is starting treatment for hair loss with 1mg Finasteride daily and 5% Minoxidil foam twice a day, along with other hair care products and supplements. He plans to document his progress monthly and is concerned about potential side effects from Finasteride.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

A 28-year-old male diagnosed with Male Pattern Baldness is using finasteride 1mg and asking if it's sufficient without minoxidil, PRP, or multivitamins. The advice given is to continue with finasteride and assess results after a year before considering additional treatments.

The user is currently using Minoxidil with melatonin, rosemary, peppermint, azelaic acid, and RU58841 for hair loss and plans to add fluridil and Pyrilutamide. They seek advice on the best Pyrilutamide source, noting Actifolic worked briefly.

Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.

The user is experiencing hair thinning and increased hair fall, and is considering using minoxidil for 3-4 months but is concerned about the long-term commitment and potential hair loss after stopping. They have tried multivitamins, serums, and shampoos, and are hesitant about starting PRP treatment.

Many are unaware of effective male pattern baldness treatments like finasteride and minoxidil, often opting for ineffective remedies. Educating others on proven treatments and potential side effects is crucial.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.

User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.

The user has been on finasteride and minoxidil since 2020 and increased dutasteride and minoxidil doses in June 2024, but still experiences hair loss. Despite trying pyrilutamide without success, opinions vary on whether the hair loss is significant, with some suggesting it might be due to lighting, angles, or a regular shedding cycle.

FalseHour6541's two-year experience with Minoxidil and Finasteride, resulting in good density on their crown; other users suggested a hair transplant to help reduce the receding hairline.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The user is treating hair loss with 1mg finasteride every other day, daily topical minoxidil, and weekly derma rolling, and is considering using hair fibers for special occasions. There is a discussion about the initial shedding phase of minoxidil treatment and the importance of consistent photo conditions to track progress.

The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.

Pyrilutamide shows promising hair growth results, but skepticism exists due to potential biases and lack of blinding in the study. Concerns about side effects and legitimacy of the product persist, with comparisons to finasteride and discussions on post-finasteride syndrome.

A user's progress with hair loss treatment, which includes pyrilutamide, dutasteride mesotherapy and topical finasteride, as well as 3 years of minoxidil use. It also discusses whether or not the poster may have had a hair transplant.

A 32-year-old male with hair loss cannot use finasteride due to erectile dysfunction and minoxidil due to scalp psoriasis. He seeks alternative treatments for his condition.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.